Neoadjuvant administration of hydroxychloroquine in a phase 1 clinical trial induced plasma Par-4 levels and apoptosis in diverse tumors.

Wang, Peng; Burikhanov, Ravshan; Jayswal, Rani; Weiss, Heidi L; Arnold, Susanne M; Villano, John L; Rangnekar, Vivek M

Wang, Peng; Burikhanov, Ravshan; Jayswal, Rani; Weiss, Heidi L; Arnold, Susanne M; Villano, John L; Rangnekar, Vivek M.

Afiliación

Wang P; Department of Internal Medicine, University of Kentucky, Lexington, Kentucky, USA.
Burikhanov R; Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA.
Jayswal R; Department of Radiation Medicine, University of Kentucky, Lexington, Kentucky, USA.
Weiss HL; Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA.
Arnold SM; Department of Internal Medicine, University of Kentucky, Lexington, Kentucky, USA.
Villano JL; Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA.
Rangnekar VM; Department of Internal Medicine, University of Kentucky, Lexington, Kentucky, USA.

Genes Cancer ; 9(5-6): 190-197, 2018 May.

Article en En | MEDLINE | ID: mdl-30603055

Palabras clave

Par-4; clinical trial; hydroxychloroquine; tumor apoptosis

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Genes Cancer Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google